ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2024

The impact of an 'evergreening' strategy nearing patent expiration on the uptake of biosimilars and public healthcare costs: a case study on the introduction of a second administration form of trastuzumab in The Netherlands.

Ghyli Kirshner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.